カテゴリー： QYResearch, 世界

世界の尿管がん薬市場 2019年

【英語タイトル】Global Ureter Cancer Drugs Market Professional Survey Report 2019

QYResearchが出版した調査資料（DATA909X17153）・商品コード：DATA909X17153
・発行会社（調査会社）：QYResearch
・発行日：2019年11月22日（※2024年版があります。お問い合わせください）
・ページ数：109
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品・ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,500 ⇒換算￥518,000見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,250 ⇒換算￥777,000見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,000 ⇒換算￥1,036,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※本調査レポートは、尿管がん薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、デュルバルマブ、メシル酸エリブリン、ペンブロリズマブ、その他に、用途別には、入院患者、外来患者にセグメント区分し、尿管がん薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・尿管がん薬の世界市場概要
・尿管がん薬の製造コスト構成分析
・尿管がん薬の開発・製造工場分析
・主要メーカーの主な指標（生産能力、売上、価格分析）
・尿管がん薬の地域別分析（生産、売上、主要メーカー、輸出・輸入）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・尿管がん薬のセグメント分析（種類別）
（デュルバルマブ、メシル酸エリブリン、ペンブロリズマブ、その他）
・尿管がん薬のセグメント分析（用途別）
（入院患者、外来患者）
・尿管がん薬の主要メーカー別分析（生産拠点、製品概要、生産・売上実績）
（Altor BioScience Corp、Eisai Co Ltd、Exelixis Inc、GlaxoSmithKline Plc、MedImmune LLC、Merck & Co Inc、）
・尿管がん薬の市場規模予測（2019年～2025年）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス（市場動向、機会、成長要因、課題、影響因子）
...
【レポートの概要】

The global Ureter Cancer Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Ureter Cancer Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Ureter Cancer Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Ureter Cancer Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Ureter Cancer Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Altor BioScience Corp
Eisai Co Ltd
Exelixis Inc
GlaxoSmithKline Plc
MedImmune LLC
Merck & Co Inc
…

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Durvalumab
Eribulin Mesylate
Pembrolizumab
Others

Segment by Application
In-Patient
Out-Patient

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Ureter Cancer Drugs
1.1 Definition of Ureter Cancer Drugs
1.2 Ureter Cancer Drugs Segment by Type
1.2.1 Global Ureter Cancer Drugs Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Durvalumab
1.2.3 Eribulin Mesylate
1.2.4 Pembrolizumab
1.2.5 Others
1.3 Ureter Cancer Drugs Segment by Applications
1.3.1 Global Ureter Cancer Drugs Consumption Comparison by Applications (2014-2025)
1.3.2 In-Patient
1.3.3 Out-Patient
1.4 Global Ureter Cancer Drugs Overall Market
1.4.1 Global Ureter Cancer Drugs Revenue (2014-2025)
1.4.2 Global Ureter Cancer Drugs Production (2014-2025)
1.4.3 North America Ureter Cancer Drugs Status and Prospect (2014-2025)
1.4.4 Europe Ureter Cancer Drugs Status and Prospect (2014-2025)
1.4.5 China Ureter Cancer Drugs Status and Prospect (2014-2025)
1.4.6 Japan Ureter Cancer Drugs Status and Prospect (2014-2025)
1.4.7 Southeast Asia Ureter Cancer Drugs Status and Prospect (2014-2025)
1.4.8 India Ureter Cancer Drugs Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Ureter Cancer Drugs
2.3 Manufacturing Process Analysis of Ureter Cancer Drugs
2.4 Industry Chain Structure of Ureter Cancer Drugs

3 Development and Manufacturing Plants Analysis of Ureter Cancer Drugs
3.1 Capacity and Commercial Production Date
3.2 Global Ureter Cancer Drugs Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Ureter Cancer Drugs
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Ureter Cancer Drugs Production and Capacity Analysis
4.2 Ureter Cancer Drugs Revenue Analysis
4.3 Ureter Cancer Drugs Price Analysis
4.4 Market Concentration Degree

5 Ureter Cancer Drugs Regional Market Analysis
5.1 Ureter Cancer Drugs Production by Regions
5.1.1 Global Ureter Cancer Drugs Production by Regions
5.1.2 Global Ureter Cancer Drugs Revenue by Regions
5.2 Ureter Cancer Drugs Consumption by Regions
5.3 North America Ureter Cancer Drugs Market Analysis
5.3.1 North America Ureter Cancer Drugs Production
5.3.2 North America Ureter Cancer Drugs Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Ureter Cancer Drugs Import and Export
5.4 Europe Ureter Cancer Drugs Market Analysis
5.4.1 Europe Ureter Cancer Drugs Production
5.4.2 Europe Ureter Cancer Drugs Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Ureter Cancer Drugs Import and Export
5.5 China Ureter Cancer Drugs Market Analysis
5.5.1 China Ureter Cancer Drugs Production
5.5.2 China Ureter Cancer Drugs Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Ureter Cancer Drugs Import and Export
5.6 Japan Ureter Cancer Drugs Market Analysis
5.6.1 Japan Ureter Cancer Drugs Production
5.6.2 Japan Ureter Cancer Drugs Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Ureter Cancer Drugs Import and Export
5.7 Southeast Asia Ureter Cancer Drugs Market Analysis
5.7.1 Southeast Asia Ureter Cancer Drugs Production
5.7.2 Southeast Asia Ureter Cancer Drugs Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Ureter Cancer Drugs Import and Export
5.8 India Ureter Cancer Drugs Market Analysis
5.8.1 India Ureter Cancer Drugs Production
5.8.2 India Ureter Cancer Drugs Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Ureter Cancer Drugs Import and Export

6 Ureter Cancer Drugs Segment Market Analysis (by Type)
6.1 Global Ureter Cancer Drugs Production by Type
6.2 Global Ureter Cancer Drugs Revenue by Type
6.3 Ureter Cancer Drugs Price by Type

7 Ureter Cancer Drugs Segment Market Analysis (by Application)
7.1 Global Ureter Cancer Drugs Consumption by Application
7.2 Global Ureter Cancer Drugs Consumption Market Share by Application (2014-2019)

8 Ureter Cancer Drugs Major Manufacturers Analysis
8.1 Altor BioScience Corp
8.1.1 Altor BioScience Corp Ureter Cancer Drugs Production Sites and Area Served
8.1.2 Altor BioScience Corp Product Introduction, Application and Specification
8.1.3 Altor BioScience Corp Ureter Cancer Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Eisai Co Ltd
8.2.1 Eisai Co Ltd Ureter Cancer Drugs Production Sites and Area Served
8.2.2 Eisai Co Ltd Product Introduction, Application and Specification
8.2.3 Eisai Co Ltd Ureter Cancer Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Exelixis Inc
8.3.1 Exelixis Inc Ureter Cancer Drugs Production Sites and Area Served
8.3.2 Exelixis Inc Product Introduction, Application and Specification
8.3.3 Exelixis Inc Ureter Cancer Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 GlaxoSmithKline Plc
8.4.1 GlaxoSmithKline Plc Ureter Cancer Drugs Production Sites and Area Served
8.4.2 GlaxoSmithKline Plc Product Introduction, Application and Specification
8.4.3 GlaxoSmithKline Plc Ureter Cancer Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 MedImmune LLC
8.5.1 MedImmune LLC Ureter Cancer Drugs Production Sites and Area Served
8.5.2 MedImmune LLC Product Introduction, Application and Specification
8.5.3 MedImmune LLC Ureter Cancer Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Merck & Co Inc
8.6.1 Merck & Co Inc Ureter Cancer Drugs Production Sites and Area Served
8.6.2 Merck & Co Inc Product Introduction, Application and Specification
8.6.3 Merck & Co Inc Ureter Cancer Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served

9 Development Trend of Analysis of Ureter Cancer Drugs Market
9.1 Global Ureter Cancer Drugs Market Trend Analysis
9.1.1 Global Ureter Cancer Drugs Market Size (Volume and Value) Forecast 2019-2025
9.2 Ureter Cancer Drugs Regional Market Trend
9.2.1 North America Ureter Cancer Drugs Forecast 2019-2025
9.2.2 Europe Ureter Cancer Drugs Forecast 2019-2025
9.2.3 China Ureter Cancer Drugs Forecast 2019-2025
9.2.4 Japan Ureter Cancer Drugs Forecast 2019-2025
9.2.5 Southeast Asia Ureter Cancer Drugs Forecast 2019-2025
9.2.6 India Ureter Cancer Drugs Forecast 2019-2025
9.3 Ureter Cancer Drugs Market Trend (Product Type)
9.4 Ureter Cancer Drugs Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Ureter Cancer Drugs Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

List of Tables and Figures
Figure Picture of Ureter Cancer Drugs
Table Global Ureter Cancer Drugs Production (K Pcs) Growth Rate Comparison by Types (2014-2025)
Figure Global Ureter Cancer Drugs Production Market Share by Types in 2018
Figure Durvalumab Product Picture
Figure Eribulin Mesylate Product Picture
Figure Pembrolizumab Product Picture
Figure Others Product Picture
Table Global Ureter Cancer Drugs Consumption (K Pcs) Comparison by Applications (2014-2025)
Figure Global Ureter Cancer Drugs Consumption Market Share by Applications in 2018
Figure In-Patient
Figure Out-Patient
Figure Global Ureter Cancer Drugs Revenue (Million USD) (2014-2025)
Figure Global Ureter Cancer Drugs Production (K Pcs) (2014-2025)
Figure North America Ureter Cancer Drugs Market Size (Million USD) (2014-2025)
Figure Europe Ureter Cancer Drugs Market Size (Million USD) (2014-2025)
Figure China Ureter Cancer Drugs Market Size (Million USD) (2014-2025)
Figure Japan Ureter Cancer Drugs Market Size (Million USD) (2014-2025)
Figure Southeast Asia Ureter Cancer Drugs Market Size (Million USD) (2014-2025)
Figure India Ureter Cancer Drugs Market Size (Million USD) (2014-2025)
Table Ureter Cancer Drugs Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Ureter Cancer Drugs in 2018
Figure Manufacturing Process Analysis of Ureter Cancer Drugs
Figure Industry Chain Structure of Ureter Cancer Drugs
Table Capacity and Commercial Production Date of Key Manufacturers
Table Global Ureter Cancer Drugs Manufacturing Plants Distribution
Table Ureter Cancer Drugs Major Manufacturers Technology Source and Market Position
Table Recent Development and Expansion Plans in Future
Table Ureter Cancer Drugs Capacity (K Pcs) of Major Manufacturers (2014-2019)
Table Ureter Cancer Drugs Production (K Pcs) of Major Manufacturers (2014-2019)
Table Ureter Cancer Drugs Production Market Share of Major Manufacturers (2014-2019)
Figure Ureter Cancer Drugs Production Share by Manufacturers in 2018
Table Ureter Cancer Drugs Revenue (Million US$) of Major Manufacturers (2014-2019)
Table Ureter Cancer Drugs Revenue Market Share of Major Manufacturers (2014-2019)
Figure Ureter Cancer Drugs Revenue Share by Manufacturers in 2018
Table Ureter Cancer Drugs Average Price (USD/Pcs) of Major Manufacturers (2014-2019)
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Global Ureter Cancer Drugs Production by Regions 2014-2019 (K Pcs)
Table Global Ureter Cancer Drugs Production Market Share by Regions 2014-2019
Figure Global Ureter Cancer Drugs Production Market Share by Regions in 2018
Table Global Ureter Cancer Drugs Revenue by Regions 2014-2019 (Million USD)
Table Global Ureter Cancer Drugs Revenue Market Share by Regions 2014-2019
Figure Global Ureter Cancer Drugs Revenue Market Share by Regions in 2018
Table Global Ureter Cancer Drugs Consumption by Regions 2014-2019 (K Pcs)
Table Global Ureter Cancer Drugs Consumption Market Share by Regions 2014-2019
Figure North America Ureter Cancer Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure North America Ureter Cancer Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table North America Ureter Cancer Drugs Production, Consumption Import and Export (K Pcs)
Figure Europe Ureter Cancer Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure Europe Ureter Cancer Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table Europe Ureter Cancer Drugs Production, Consumption Import and Export (K Pcs)
Figure China Ureter Cancer Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure China Ureter Cancer Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table China Ureter Cancer Drugs Production, Consumption Import and Export (K Pcs)
Figure Japan Ureter Cancer Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure Japan Ureter Cancer Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table Japan Ureter Cancer Drugs Production, Consumption Import and Export (K Pcs)
Figure Southeast Asia Ureter Cancer Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure Southeast Asia Ureter Cancer Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table Southeast Asia Ureter Cancer Drugs Production, Consumption Import and Export (K Pcs)
Figure India Ureter Cancer Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure India Ureter Cancer Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table India Ureter Cancer Drugs Production, Consumption Import and Export (K Pcs)
Figure Global Consumption Ureter Cancer Drugs Market Share by Application (2014-2019)
Figure Global Value (Consumption) Ureter Cancer Drugs Market Share by Application (2014-2019)
Table Altor BioScience Corp Ureter Cancer Drugs Production Sites and Area Served
Table Altor BioScience Corp Ureter Cancer Drugs Product Introduction, Application and Specification
Table Altor BioScience Corp Ureter Cancer Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Altor BioScience Corp Ureter Cancer Drugs Production Growth Rate (2014-2019)
Table Altor BioScience Corp Ureter Cancer Drugs Production Market Share (2014-2019)
Figure Altor BioScience Corp Ureter Cancer Drugs Revenue Market Share (2014-2019)
Table Altor BioScience Corp Ureter Cancer Drugs Main Business and Markets Served
Table Eisai Co Ltd Ureter Cancer Drugs Production Sites and Area Served
Table Eisai Co Ltd Ureter Cancer Drugs Product Introduction, Application and Specification
Table Eisai Co Ltd Ureter Cancer Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Eisai Co Ltd Ureter Cancer Drugs Production Growth Rate (2014-2019)
Table Eisai Co Ltd Ureter Cancer Drugs Production Market Share (2014-2019)
Figure Eisai Co Ltd Ureter Cancer Drugs Revenue Market Share (2014-2019)
Table Eisai Co Ltd Ureter Cancer Drugs Main Business and Markets Served
Table Exelixis Inc Ureter Cancer Drugs Production Sites and Area Served
Table Exelixis Inc Ureter Cancer Drugs Product Introduction, Application and Specification
Table Exelixis Inc Ureter Cancer Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Exelixis Inc Ureter Cancer Drugs Production Growth Rate (2014-2019)
Table Exelixis Inc Ureter Cancer Drugs Production Market Share (2014-2019)
Figure Exelixis Inc Ureter Cancer Drugs Revenue Market Share (2014-2019)
Table Exelixis Inc Ureter Cancer Drugs Main Business and Markets Served
Table GlaxoSmithKline Plc Ureter Cancer Drugs Production Sites and Area Served
Table GlaxoSmithKline Plc Ureter Cancer Drugs Product Introduction, Application and Specification
Table GlaxoSmithKline Plc Ureter Cancer Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table GlaxoSmithKline Plc Ureter Cancer Drugs Production Growth Rate (2014-2019)
Table GlaxoSmithKline Plc Ureter Cancer Drugs Production Market Share (2014-2019)
Figure GlaxoSmithKline Plc Ureter Cancer Drugs Revenue Market Share (2014-2019)
Table GlaxoSmithKline Plc Ureter Cancer Drugs Main Business and Markets Served
Table MedImmune LLC Ureter Cancer Drugs Production Sites and Area Served
Table MedImmune LLC Ureter Cancer Drugs Product Introduction, Application and Specification
Table MedImmune LLC Ureter Cancer Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table MedImmune LLC Ureter Cancer Drugs Production Growth Rate (2014-2019)
Table MedImmune LLC Ureter Cancer Drugs Production Market Share (2014-2019)
Figure MedImmune LLC Ureter Cancer Drugs Revenue Market Share (2014-2019)
Table MedImmune LLC Ureter Cancer Drugs Main Business and Markets Served
Table Merck & Co Inc Ureter Cancer Drugs Production Sites and Area Served
Table Merck & Co Inc Ureter Cancer Drugs Product Introduction, Application and Specification
Table Merck & Co Inc Ureter Cancer Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Merck & Co Inc Ureter Cancer Drugs Production Growth Rate (2014-2019)
Table Merck & Co Inc Ureter Cancer Drugs Production Market Share (2014-2019)
Figure Merck & Co Inc Ureter Cancer Drugs Revenue Market Share (2014-2019)
Table Merck & Co Inc Ureter Cancer Drugs Main Business and Markets Served
Figure Global Ureter Cancer Drugs Production (K Pcs) Growth Rate Forecast 2019-2025
Figure Global Ureter Cancer Drugs Revenue (Million USD) Growth Rate Forecast 2019-2025
Figure Global Ureter Cancer Drugs Sales Price (USD/Pcs) Forecast 2019-2025
Figure North America Ureter Cancer Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure North America Ureter Cancer Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Europe Ureter Cancer Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Europe Ureter Cancer Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure China Ureter Cancer Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure China Ureter Cancer Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Japan Ureter Cancer Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Japan Ureter Cancer Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Southeast Asia Ureter Cancer Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Southeast Asia Ureter Cancer Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure India Ureter Cancer Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure India Ureter Cancer Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Table Global Production (K Pcs) of Ureter Cancer Drugs by Type (2019-2025)
Table Global Consumption (K Pcs) of Ureter Cancer Drugs by Application (2019-2025)
Table Ureter Cancer Drugs Distributors List
Table Ureter Cancer Drugs Customers List
Table Market Key Trends
Table Key Opportunities
Table Market Key Drivers
Table Key Challenges
Table Key Influence Factors
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

Altor BioScience Corp、Eisai Co Ltd、Exelixis Inc、GlaxoSmithKline Plc、MedImmune LLC、Merck & Co Inc、

★調査レポート[世界の尿管がん薬市場 2019年] (コード：DATA909X17153)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の尿管がん薬市場 2019年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のLAMEA腫瘍/抗癌剤市場 2019年
    DATA909X10268 / QYResearch / 2019年11月20日 / ※本調査レポートは、LAMEA腫瘍/抗癌剤の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、血液癌、乳癌、胃腸癌、前立腺癌、その他に、用途別には、化学療法、標的療法、免疫療法（生物学的療法）、ホルモン療法、その他にセグメント区分し、LAMEA腫瘍/抗癌剤の世界市場を分析しました。 ・エグゼクティブ・サマリー ・LAMEA腫瘍/抗癌剤の世界市場概要 ・LAMEA腫瘍/抗癌剤の製造コスト構成分析 ・LAMEA腫瘍/抗癌剤の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・LAMEA腫瘍/抗癌剤の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・LAMEA腫瘍/抗癌剤のセグメント分析（種類別） （血液癌、乳癌、胃腸癌、前立腺癌、その他）...The global LAMEA Oncology/Anti-cancer drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on LAMEA Oncology/Anti-cancer drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall LAMEA Oncology/Anti-cancer drugs market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of LAMEA Oncology/Anti-cancer drugs in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 食道癌治療薬の世界市場：規模・現状・予測2019-2025
    DATA909X18452 / QYResearch / 2019年11月25日 / ※当調査レポートでは、食道癌治療薬の世界市場について調査・分析し、食道癌治療薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（フルオロウラシル、シスプラチン、ドセタキセル、カルボプラチン、その他）、用途別（標的療法、化学療法）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の食道癌治療薬市場動向 ・主要企業別マーケットシェア ・食道癌治療薬の種類別市場規模2014-2019 （フルオロウラシル、シスプラチン、ドセタキセル、カルボプラチン、その他） ・食道癌治療薬の用途別市場規模2014-2019 （標的療法、化学療法） ・食道癌治療薬の北米市場：主要企業・種類別/用途別市場規模 ・食道癌治療薬のヨーロッパ市場：主要企業・種類別/用途別市場規模...Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and the stomach.Symptoms often include difficulty in swallowing and weight loss.Other symptoms may include pain when swallowing, a hoarse voice, enlarged lymph nodes ("glands") around the collarbone, a dry cough, and possibly coughing up or vomiting blood.Various combinations of drugs such as fluorouracil, cisplatin, docetaxel, and carboplatin are involved in standard chemotherapy regimens for the treatment of esophageal cancer. These drugs are selected based on adverse drug reactions and cancer subtypes. To ensure patient access to available therapeutics, governments in developed countries are introducing reimbursement...
  • 世界の泌尿器がん治療薬市場 2019年
    DATA909X17175 / QYResearch / 2019年11月22日 / ※本調査レポートは、泌尿器がん治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、ゾーフィゴ(塩化ラジウム223)、ジェブタナ(カバジタキセル)、インライタ(アキシチニブ)、ヴォトリエント(パゾパニブ塩酸塩)、スーテント(スニチニブリンゴ酸塩)、ザイティガ(アビラテロン酢酸エステル)、イクスタンジ(エンザルタミド)、オプジーボ(ニボルマブ)、プロベンジ(シプリューセルT)に、用途別には、病院、医学研究所、その他にセグメント区分し、泌尿器がん治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・泌尿器がん治療薬の世界市場概要 ・泌尿器がん治療薬の製造コスト構成分析 ・泌尿器がん治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・泌尿器がん治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・泌尿器がん治療薬のセグメント分析（種類別） （ゾーフィゴ(塩化ラジウム223)、ジェブタナ(カバジタキセル)、インライタ(アキシチニブ)、ヴォトリエント(パゾパニブ塩酸塩)、スーテント(スニチニブリンゴ酸塩)、ザイティガ(アビラテロン酢酸エステル)、イクスタンジ(エンザルタミド)、オプジーボ(ニボルマブ)、プロベンジ(シプリューセルT)）...The global Urological Cancer Therapeutics Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Urological Cancer Therapeutics Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Urological Cancer Therapeutics Drugs market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Urological Cancer Therapeutics Drugs in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer...
  • 非小細胞肺がん薬の世界市場：規模・現状・予測2019-2025
    DATA909X18757 / QYResearch / 2019年11月25日 / ※当調査レポートでは、非小細胞肺がん薬の世界市場について調査・分析し、非小細胞肺がん薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（生物製剤、小分子標的療法、化学療法、その他）、用途別（肺腺がん、扁平上皮肺がん、大細胞肺がん）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の非小細胞肺がん薬市場動向 ・主要企業別マーケットシェア ・非小細胞肺がん薬の種類別市場規模2014-2019 （生物製剤、小分子標的療法、化学療法、その他） ・非小細胞肺がん薬の用途別市場規模2014-2019 （肺腺がん、扁平上皮肺がん、大細胞肺がん） ・非小細胞肺がん薬の北米市場：主要企業・種類別/用途別市場規模 ・非小細胞肺がん薬のヨーロッパ市場：主要企業・種類別/用途別市場規模...Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.The strong drug pipeline and drug approvals are one of the critical factors that will trigger the non-small cell lung cancer drugs market growth during the forecast period. With the increase in the prevalence of lung cancer, the need for a strong pipeline of disease-modifying drugs is also increasing. In 2018, the global Non-small Cell Lung Cancer Drugs market size was xx million US$ and it is expected to reach xx million US$ by...

    • ◆H&Iグローバルリサーチのお客様（例）◆